advertisement
Abstract #8753 Published in IGR 5-1
Treatment of rubeosis iridis with photodynamic therapy with verteporfin: a new therapeutic and prophylactic option for patients with the risk of neovascular glaucoma?
Müller AV; Ruokonen P; Schellenbeck M; Hartmann C; Tetz MOphthalmic Research 2003; 35: 60-64
Patients with ischemic retinopathy who show iris neovascularization despite panretinal laser photocoagulation (PRP) very often develop neovascular glaucoma. Photodynamic therapy (PDT) has been shown to occlude neovascularization without damage to the physiological vessels or adjacent tissue in the treatment of choroidal neovascularization (CNV), and may also be of value for patients with neovascular glaucoma who do not benefit from PRP. The first results of a monocenter, open-label, intra-individual controlled, pilot phase I/II, dose-finding study demonstrate that PDT with verteporfin is capable of occluding neovascular vessels for a defined period of time without damaging the adjacent tissue or physiological iris vessels. Whether this vessel occlusion will have an impact on the progression of rubeosis or neovascular glaucoma will be the subject of further investigation.
Dr. V.A. Müller, Department of Ophthalmology, Charit‚ Klinikum Campus Virchow, Augustenburger Platz 1, D-13353 Berlin, Germany. valeska_mueller@hotmail.com
Classification:
9.4.5.1 Neovascular glaucoma (Part of: 9 Clinical forms of glaucomas > 9.4 Glaucomas associated with other ocular and systemic disorders > 9.4.5 Glaucomas associated with disorders of the retina, choroid and vitreous)
